ANVS
Annovis Bio, Inc.
NYSE · Healthcare · Biotechnology · US
$1.39
+0.72%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +12.3%
- Free cash flow
- -75.5%
- Operating cash flow
- -75.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +85.2%
- EPS
- +43.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -26.9%
- EBIT
- -11.2%
- Net income
- -17.3%
- EPS
- +30.7%
- Free cash flow
- -17.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026